论文部分内容阅读
大肠癌是我国常见十大癌症之一,其发病率有逐年上升趋势.我国大肠癌根治术后5年生存率约50.21%,近一半的患者死于复发和转移,且多在术后3年内.既往认为大肠癌对化疗不敏感,遂有化疗对之前景暗淡之慨.但经过近10年的努力,特别是在生化调节剂理论指导下不同药物的联合使用,以及不同给药途径的配合,使内科治疗的有效率明显改观.本文就这一领域内近10年来内科临床治疗的进展予以综述.
Colorectal cancer is one of the ten most common cancers in China. Its incidence rate has been increasing year by year. The 5-year survival rate after radical resection of colon cancer in China is about 50.21%. Nearly half of patients died of recurrence and metastasis, and most of them died within 3 years after surgery. It was previously thought that colorectal cancer is insensitive to chemotherapy, and there is a dim cheek of chemotherapy. However, after nearly 10 years of hard work, especially the joint use of different drugs under the guidance of the theory of biochemical modulators, and the cooperation of different routes of administration. , Make the efficiency of medical treatment significantly improved. This article summarizes the progress of clinical treatment of internal medicine in this field in the past 10 years.